SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 973-977. Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-07-2864. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-07-2864v1 105/3/973    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mesa, R. A. Articles by Tefferi, A. Search for Related Content PubMed PubMed Citation Articles by Mesa, R. A. Articles by Tefferi, A. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases Ruben A. Mesa, Chin-Yang Li, Rhett P. Ketterling, Georgene S. Schroeder, Ryan A. Knudson, and Ayalew Tefferi From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN. Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Passamonti, E. Rumi, M. Caramella, C. Elena, L. Arcaini, E. Boveri, C. Del Curto, D. Pietra, L. Vanelli, P. Bernasconi, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood, April 1, 2008; 111(7): 3383 - 3387. [Abstract] [Full Text] [PDF] E. Rumi, F. Passamonti, M. G. Della Porta, C. Elena, L. Arcaini, L. Vanelli, C. Del Curto, D. Pietra, E. Boveri, C. Pascutto, et al. Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation J. Clin. Oncol., December 10, 2007; 25(35): 5630 - 5635. [Abstract] [Full Text] [PDF] G. L. Chen and J. T. Prchal X-linked clonality testing: interpretation and limitations Blood, September 1, 2007; 110(5): 1411 - 1419. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] P. Guglielmelli, R. Zini, C. Bogani, S. Salati, A. Pancrazzi, E. Bianchi, F. Mannelli, S. Ferrari, M.-C. Le Bousse-Kerdiles, A. Bosi, et al. Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1) Stem Cells, January 1, 2007; 25(1): 165 - 173. [Abstract] [Full Text] [PDF] T. Mercher, G. Wernig, S. A. Moore, R. L. Levine, T.-L. Gu, S. Frohling, D. Cullen, R. D. Polakiewicz, O. A. Bernard, T. J. Boggon, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model Blood, October 15, 2006; 108(8): 2770 - 2779. [Abstract] [Full Text] [PDF] C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF] J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek, M. Beran, E. Estey, H. M. Kantarjian, and J.-P. J. Issa JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood, November 15, 2005; 106(10): 3370 - 3373. [Abstract] [Full Text] [PDF] A. M. Vannucchi, A. Pancrazzi, P. Guglielmelli, S. Di Lollo, C. Bogani, G. Baroni, L. Bianchi, A. R. Migliaccio, A. Bosi, and F. Paoletti Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis Am. J. Pathol., September 1, 2005; 167(3): 849 - 858. [Abstract] [Full Text] [PDF] K. Strasser-Weippl, M. Steurer, M. Kees, F. Augustin, A. Tzankov, S. Dirnhofer, M. Fiegl, H. Gisslinger, N. Zojer, and H. Ludwig Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia Blood, May 15, 2005; 105(10): 4146 - 4146. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020